This study was undertaken to evaluate the association between age at diagnosis, patterns of care, and outcome among elderly individuals with anaplastic astrocytoma (AA) and glioblastoma multiforme (GBM).
Using the Surveillance, Epidemiology and End Results database, the authors identified 1753 individuals with primary GBM and 205 individuals with primary AA (diagnosed between June 1991 and December 1999) who were 66 years and older and whose records were linked to Medicare information. To facilitate gathering of prediagnosis comorbidity and postdiagnosis treatment information, only those individuals were included who had the same Medicare coverage for 6 months before and 12 months after diagnosis. The odds of undergoing various combinations of treatments and the associations with outcome were calculated by tumor type and age and adjusted by various predictors.
Age was not associated with treatment differences in individuals with AA. Very elderly individuals (≥ 75 years old) with GBM were more likely to have biopsy only (odds ratio [OR] 2.53, 95% confidence interval [CI] 1.78–3.59), surgery only (OR 1.47, 95% CI 1.15–1.87), or biopsy and radiation (OR 1.39, 95% CI 1.07–1.82) and were less likely to receive multimodal therapy. Regardless of patient age or lesion histological characteristics, survival was decreased in patients treated with biopsy only. Individuals with GBM who had surgery only or biopsy and radiation had worse outcomes than individuals treated with surgery and radiation. There were no differences in survival by lesion histological characteristics. Very elderly individuals with malignant astrocytomas were more likely to receive limited treatment (most pronounced in individuals with GBM). Survival variation correlated with treatment combinations.
These findings suggest that in clinical neurooncology patient age is associated with not receiving effective therapies and hence worse prognosis.
Abbreviations used in this paper: AA = anaplastic astrocytoma; CI = confidence interval; GBM = glioblastoma multiforme; HMO = health maintenance organization; HR = hazard ratio; ICD-9-CM = International Classification of Diseases, Ninth Version, Clinical Modification; ICD-O-3 = ICD for Oncology, Third Edition; MED-PAR = Medicare Provider Analysis and Review; NCH = National Claims History; OR = odds ratio; OUTSAF = Outpatient Standard Analytical File; SEER = Surveillance, Epidemiology, and End Results.
Address correspondence to: Jill S. Barnholtz-Sloan, Ph.D., Assistant Professor, Case Western Reserve University School of Medicine and Case Comprehensive Cancer Center, 11100 Euclid Avenue, Cleveland, Ohio, 44106-5065. email:
Current address for Dr. Chamberlain: Department of Neurology, Division of Neuro-Oncology, University of Washington, and Seattle Cancer Care Alliance.
CBTRUS: Primary Brain Tumors in the United States: Statistical Report 1998–2002Hinsdale, IllCentral Brain Tumor Registry of the United States2005. (http://www.cbtrus.org/reports/2005-2006/2006report.pdf) [Accessed 15 November 2007]
ChangSMParneyIFMcDermottMBarkerFGIISchmidtMHHuangW: Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. J Neurosurg98:1175–11812003
DavisFGMcCarthyBJFreelsSKupelianVBondyML: The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data. Cancer85:485–4911999
MagriniSMRicardiUSantoniRKrengliMLupattelliMCafaroI: Patterns of practice and survival in a retrospective analysis of 1722 adult astrocytoma patients treated between 1985 and 2001 in 12 Italian radiation oncology centers. Int J Radiat Oncol Biol Phys65:788–7992006
MahaleyMSJrMettlinCNatarajanNLawsERJrPeaceBB: Analysis of patterns of care of brain tumor patients in the United States: a study of the Brain Tumor Section of the AANS and the CNS and the Commission on Cancer of the ACS. Clin Neurosurg36:347–3521990
MarijnenCAvan den BergSMvan DuinenSGVoormolenJHNoordijkEM: Radiotherapy is effective in patients with glioblastoma multiforme with a limited prognosis and in patients above 70 years of age: a retrospective single institution analysis. Radiother Oncol75:210–2162005
MirimanoffROGorliaTMasonWVan den BentMJKortmannRDFisherB: Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol24:2563–25692006
MohanDSSuhJHPhanJLKupelianPACohenBHBarnettGH: Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution. Int J Radiat Oncol Biol Phys42:981–9871998